Although numerous studies have highlighted PLK1 as a promising therapeutic target for SCLC [20, 46], a phase II trial of PLK1 inhibitor BI-2536 as a monotherapy demonstrated limited activity [2, 47]. This evidence concerns the gene PLK1 and small cell lung carcinoma.